Tirzepatide and semaglutide are the two active ingredients behind the most popular weight loss medications on the market, so it can be easy to mix them up or not be sure which one is right for you.
They're related, but they're not the same. This article will cover what they are, how they work, and how you can think about which medication might be ideal for your lifestyle, health history, and goals.
What is semaglutide?
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist, and by mimicking this hormone, it helps slow the digestion of food, reduce appetite and cravings for food, which helps promote weight loss. It's the active ingredient in Ozempic, FDA-approved for type 2 diabetes, and Wegovy, which is FDA-approved for chronic weight management, cardiovascular risk reduction, and MASH, a liver condition. Wegovy comes as a weekly injection or a daily pill.
What is tirzepatide?
Tirzepatide is a dual GLP-1 and GIP receptor agonist. It mimics both GLP-1 and GIP hormones, helping slow digestion, appetite, and food cravings, but with stronger effects as it affects two hormones. It's the active ingredient in Mounjaro, FDA-approved for type 2 diabetes, and Zepbound, which is FDA-approved for chronic weight management and moderate to severe obstructive sleep apnea in adults with obesity. Zepbound comes as a weekly injection, either a prefilled pen or a vial and syringe.
Tirzepatide vs semaglutide for weight loss
The clearest answer comes from SURMOUNT-5, a head-to-head clinical trial that compared tirzepatide and semaglutide against each other directly, rather than comparing each against a placebo. The researchers followed a total of 751 participants, all obese but without type 2 diabetes, all randomized in a 1:1 ratio, who lost an average of 20.2% of their body weight on tirzepatide, while participants on semaglutide lost 13.7% over 72 weeks.
A 2025 retrospective study of patients prescribed either tirzepatide or semaglutide found that patients on tirzepatide lost more weight than semaglutide participants over 6 months. Interestingly, weight loss did not differ significantly in patients who had type 2 diabetes.
In a 2024 cohort study, overweight or obese adults receiving semaglutide or tirzepatide were compared between May, 2022 and September, 2023. The results also confirmed that tirzepatide was associated with greater weight loss than semaglutide.
While the data from multiple studies suggest that tirzepatide is associated with superior weight loss to semaglutide, it’s important to note that these results don’t guarantee that tirzepatide will work better for you than semaglutide. Your own results depend on the dose, how consistently you take it, and other individual factors like genetics and lifestyle.
What happens if you stop taking either medication
Both semaglutide and tirzepatide are meant for long-term use, not a few weeks or months, and stopping either one tends to reverse much of the progress.
In SURMOUNT-4, participants who lost an average of 20.9% of their body weight over an initial 36 weeks on tirzepatide continued losing an additional 5.5% if they stayed on treatment, but regained 14% of their body weight over the following year if they switched to a placebo.
In a similar randomized controlled trial, STEP 4, the results showed a similar basic pattern. The people who continued taking semaglutide lost an additional 7.9% of body weight, while those on placebo regained 6.9%.
The two trials aren't directly comparable, since the starting weight loss and follow-up periods differ. But the takeaway holds for both medications. The takeaway is that regardless of which medication you take, it’s worth thinking about it as a long-term commitment, rather than a temporary weight loss program you start and complete. Stopping either medication consistently showed that people regained some of the weight they lost.
Key differences
How they work
Semaglutide mimics GLP-1 alone, while tirzepatide mimics GLP-1 and a second hormone called GIP (glucose-dependent insulinotropic polypeptide). GLP-1 is a hormone your gut releases after eating, which slows down digestion and helps to regulate blood sugar.
Researchers believe the added GIP activity may further help regulate food intake and may also enhance GLP-1 activity, which is one theory for why tirzepatide has outperformed semaglutide in trials.
It's worth noting that both medications still work through the same core pathway, so the difference between them is more a matter of degree than of two completely different approaches.
How dose differs
Semaglutide is more flexible in how it’s taken. Semaglutide comes as a weekly injection or a daily pill, so it’s a great option for people who’d rather avoid needles.
Tirzepatide currently doesn't have an FDA-approved pill option and is available as a prefilled pen or a vial and syringe. Both medications follow a titration period. In other words, the dosage starts small and is increased gradually to minimize potential side effects like nausea and stomach issues.
However, the schedules differ:
-
Zepbound starts at 2.5mg weekly for 4 weeks, then it increases in 2.5mg increments roughly every 4 weeks up to a maintenance dose of 5mg, 10mg, or 15mg.
-
Wegovy injections start at 0.25 mg weekly and increase in smaller steps before reaching a maintenance dose of up to 2.4 mg, or, more recently, an FDA-approved 7.2 mg dose for some cases, taking a few months longer to reach this final dose compared to tirzepatide.
FDA-approved indications
Both tirzepatide and semaglutide are FDA-approved for chronic weight management in obese adults or overweight adults with at least one weight-related condition, like type 2 diabetes.
They also have other applications:
-
Zepbound (tirzepatide) is also approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
-
Wegovy (semaglutide) is also approved to reduce cardiovascular risk in adults with established heart disease and obesity or overweight, and to treat MASH, a liver disease, in adults with moderate to advanced liver scarring.
Side effects
Tirzepatide and semaglutide share largely the same side effect profile, since both slow digestion and affect the same GLP-1 pathway. Side effects tend to be dose-dependent, meaning they're more likely at higher doses and are most common early on, while the dose is still increasing.
The most common side effects include:
-
Nausea, vomiting, and diarrhea
-
Constipation and abdominal pain
-
Indigestion or heartburn
-
Fatigue
-
Injection site reactions
-
Hair loss
Both drugs also carry a risk of thyroid C-cell tumors as a boxed warning, seen in animal studies, along with warnings about pancreatitis, gallbladder problems, and kidney injury due to dehydration.
Some reports show similar side effect risks between the two drugs, but a 2025 meta-analysis of 13 randomized controlled trials found that tirzepatide carries a significantly higher risk of mild GI adverse events than semaglutide, while semaglutide alone significantly raises the risk of gallbladder disease and cholelithiasis.
It's worth noting that individual responses vary. Some people tolerate one medication better than the other.
Cost and accessibility
The pricing for brand names has shifted a lot over the past year, so treat these figures as a snapshot. Right now, list prices for Zepbound and Wegovy both run over $1,000 a month before insurance, though most people don't pay full price. Some savings programs can bring that price down for people who qualify.
Insurance coverage still varies, and many plans don't cover GLP-1s for weight loss. As of July 2026, Medicare covers Wegovy and Zepbound's KwikPen for weight loss at $50 a month for eligible patients.
Compounded versions of both drugs are also available through some pharmacies, though they aren't FDA-approved and aren't the same as the brand-name product.
How to decide which is right for you
There’s no single best choice for medication. The decision won’t be based on which performs better in clinical trials, but rather on your priorities, history, and what your insurance will cover. Your healthcare provider will weigh these factors and help you decide which option to choose.
Questions worth considering when discussing your options:
-
Is maximum weight loss your top priority, or are the other benefits, like cardiovascular risk reduction or treating MASH, also relevant?
-
Do you have a strong preference for a pill over an injection?
-
Do you have other conditions, like heart disease, sleep apnea, or liver disease, that might make one medication more appropriate?
-
Which medication does your insurance plan cover, and at what cost to you?
-
Have you tried a GLP-1 medication before? If so, did it work well, and how did you tolerate it?
The bottom line
Tirzepatide and semaglutide both mimic gut hormones like GLP-1 and GIP, slowing digestion and lowering appetite. Tirzepatide also mimics GIP, unlike semaglutide, which only mimics GLP-1, but both medications are proven to promote weight loss.
Tirzepatide has led to greater weight loss in head-to-head clinical trials, but semaglutide also offers a pill option and has broader FDA approval for other cardiovascular and liver conditions.
While on average tirzepatide leads to greater weight loss, the right choice comes down to your health history, your priorities, and a conversation with your healthcare provider, not which drug is more talked about online.
